Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 01, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 153,322 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on October 30, 2006, and the Company was advised of it on October 31, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond this standard disclosure are mentioned.
Investor Verification Points
- Verify the total number of shares transferred (153,322) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the transaction date (October 30, 2006) versus the notification date (October 31, 2006).
- Review the status of the GSK Trust as a discretionary trust for employee beneficiaries.
- Note that this filing does not contain financial results; investors should refer to Form 20-F for financial data.